Li Ka-Shing’s CK Life Unit Eyes China Fast Track for Cancer Vaccine Pipeline

Why It Matters

IITs give CK a first‑to‑market edge in China’s booming immunotherapy market, turning R&D outlays into potential revenue streams.

Key Takeaways

• CK launches Sequencio Therapeutics to develop cancer vaccines
• IITs shorten Chinese trial start from 18‑24 months to months
• Two vaccine candidates target breast, colorectal cancers, trial 2027
• CK’s 2025 loss ≈ $24 million, betting on vaccine growth
• Global funding sought across Hong Kong, China, US, Europe

Pulse Analysis

China’s regulator‑driven investigator‑initiated trial (IIT) framework is reshaping early‑stage drug development. Launched in 2021, the scheme lets hospital investigators start human studies without the lengthy national drug‑approval process, cutting the typical 18‑ to 24‑month lead time to a few months. For biotech firms, this translates into faster safety read‑outs and earlier market positioning. CK Life Sciences is leveraging the pathway through its new Hong Kong subsidiary, Sequencio Therapeutics, to accelerate a portfolio of cancer‑vaccine candidates in the Greater Bay Area and mainland hospitals.

The vaccine approach differs from conventional oncology drugs that inhibit tumor growth; instead, it trains the immune system to recognize and eradicate residual disease. Sequencio’s pre‑clinical pipeline includes roughly 20 candidates, with two programs focused on high‑relapse cancers such as breast and colorectal tumours slated for first‑in‑human trials by late 2027 or early 2028. If successful, these immunotherapies could capture a share of China’s projected $30 billion oncology market, where preventive and adjuvant treatments are gaining regulatory and payer support.

CK Life reported a 2025 net loss of HK$186.8 million (about $24 million), but the company is channeling rising R&D spend into the vaccine platform as a long‑term growth engine. By courting investors from Hong Kong, mainland China, the United States and Europe, Sequencio aims to diversify its capital base while gathering multi‑regional clinical data. Early data from IITs can feed into formal submissions to both Chinese and Western regulators, giving CK a potential first‑to‑market advantage and a pathway to convert its current deficit into sustainable revenue.